Developing E-health Services (DES): The Feasibility and Acceptability of Video-conferencing for Adults With Depression (DES)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03288506|
Recruitment Status : Completed
First Posted : September 20, 2017
Last Update Posted : August 29, 2018
Depression impacts 1 in 5 people in the United Kingdom and is a significant risk factor for self-harming behaviours and suicide. Research has shown that those experiencing depression may feel embarrassed about seeking help from a health professional and ultimately decide not to seek support at all. This project seeks to give those people an alternative option to face-to-face support by developing a new online service using video conferencing technology. In previous studies, this technology has shown to be beneficial in treating a number of mental health problems. It may also be less expensive to run. However, as no widely available services of this type exist in the UK the full extent of potential benefits is unknown. The project seeks to answer the following questions:
- What is the likely interest in video conferencing services for depression?
- Which groups of people are likely to use the service?
- How much will this service cost?
- How much change is likely to occur when receiving therapy via video conferencing?
In order to answer these questions, Queens University Belfast are collaborating with AWARE NI, the national depression charity for Northern Ireland. Recruitment of participants who are interested in the service and delivery of the video conferencing support groups will be through AWARE NI. Results will be compared from groups that receive the video-conferencing service and those who are on a waiting list. Participants in both groups will be asked to complete surveys and take part in interviews before and after the therapy takes place. The study will have two main phases:
Phase 1: The development and in-house testing of an intervention protocol tailored towards Video Conferencing (VC) based delivery of current face-to-face peer support services. This will include interviews with facilitators, staff and current AWARE NI service users and observations of face to face groups.
Phase 2: Delivery of an 8-week group based VC support service for adults with depression. A between groups design comparing the intervention group and a waiting list control group will be used. Outcome measures will be recorded at baseline, week eight and six months using validated measures. Qualitative data in the form of interviews and fieldwork observations will also be gathered during this 8-week period.
Results will be used to inform development of a larger trial to test the effectiveness of group based video conferencing for adults with depression.
|Condition or disease||Intervention/treatment||Phase|
|Depression||Behavioral: Google Hangout (VC) group||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Developing E-health Services (DES): The Feasibility and Acceptability of Group Based Video-conferencing for Adults With Depression|
|Actual Study Start Date :||October 13, 2016|
|Actual Primary Completion Date :||January 30, 2018|
|Actual Study Completion Date :||June 30, 2018|
Experimental: Google Hangout (VC) group
This group receive peer led support for depression via Google Hangouts for 8-weeks
Behavioral: Google Hangout (VC) group
Feasibility and acceptability of online peer support groups for adults with depression. Groups will be delivered using video-conferencing technology (Google Hangouts).
No Intervention: Waiting list control group
- PHQ9 [ Time Frame: Six months ]Depression Measure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03288506
|Belfast, Antrim, United Kingdom, BT15 2GG|
|Principal Investigator:||Paul Best, PhD||Queen's University, Belfast|